All Stories

  1. Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines

    Article • Nature Communications, February 2022, Springer Science + Business Media

    Dr Nancy L Haigwood

  2. Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis

    Article • Nature Communications, February 2022, Springer Science + Business Media

    Dr Nancy L Haigwood

  3. CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques

    Article • Frontiers in Immunology, October 2021, Frontiers

    Dr Nancy L Haigwood

  4. A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque

    Article • Vaccine, September 2021, Elsevier

    Dr Nancy L Haigwood

  5. Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding

    Article • Journal of Virology, August 2021, ASM Journals

    Dr Nancy L Haigwood

  6. Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques

    Article • PLoS Pathogens, July 2021, PLOS

    Dr Nancy L Haigwood

  7. Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission

    Article • Nature Communications, June 2021, Springer Science + Business Media

    Dr Nancy L Haigwood

  8. Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic

    Article • Frontiers in Public Health, May 2021, Frontiers

    Dr Nancy L Haigwood

  9. Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques

    Article • npj Vaccines, March 2021, Springer Science + Business Media

    Dr Nancy L Haigwood

  10. Polyfunctional Tier 2–Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor

    Article • The Journal of Immunology, March 2021, Oxford University Press (OUP)

    Dr Nancy L Haigwood

  11. Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine–Induced Anti-V2 Antibodies Alone

    Article • The Journal of Immunology, March 2021, Oxford University Press (OUP)

    Dr Nancy L Haigwood

  12. Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge

    Article • Frontiers in Immunology, February 2021, Frontiers

    Dr Nancy L Haigwood

  13. ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics

    Article • Cell Host & Microbe, November 2020, Elsevier

    Dr Nancy L Haigwood

  14. An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques

    Article • Journal of Virology, August 2020, ASM Journals

    Dr Nancy L Haigwood

  15. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development

    Article • Frontiers in Immunology, June 2020, Frontiers

    Dr Nancy L Haigwood

  16. Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines

    Article • Vaccine, May 2020, Elsevier

    Dr Nancy L Haigwood

  17. Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure

    Article • Current HIV/AIDS Reports, May 2020, Springer Science + Business Media

    Dr Nancy L Haigwood

  18. Cloning and functional testing of rhesus macaque (Macaca mulatta) IL‐9 and IL‐33

    Article • Journal of Medical Primatology, February 2020, Wiley

    Dr Nancy L Haigwood

  19. Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity

    Article • Nature Communications, January 2020, Springer Science + Business Media

    Dr Nancy L Haigwood

  20. A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

    Article • Cell Host & Microbe, September 2019, Elsevier

    Dr Nancy L Haigwood

  21. Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses

    Article • Cell Reports, July 2019, Elsevier

    Dr Nancy L Haigwood

  22. Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology

    Article • Journal of Virology, June 2019, ASM Journals

    Dr Nancy L Haigwood

  23. Human natural killer cells mediate adaptive immunity to viral antigens

    Article • Science Immunology, May 2019, American Association for the Advancement of Science

    Dr Nancy L Haigwood

  24. Antibodies Tip the Balance Towards an HIV Cure

    Article • Trends in Immunology, May 2019, Elsevier

    Dr Nancy L Haigwood

  25. IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine

    Article • Vaccine, April 2019, Elsevier

    Dr Nancy L Haigwood

  26. Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques

    Article • Journal of Virology, March 2019, ASM Journals

    Dr Nancy L Haigwood

  27. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth

    Article • PLOS One, December 2018, PLOS

    Dr James E Crowe, Dr Nancy L Haigwood

  28. Tribute to Bonnie Mathieson

    Article • Journal of Medical Primatology, September 2018, Wiley

    Dr Nancy L Haigwood

  29. Antibodies pose a double threat to HIV

    Article • Nature, September 2018, Springer Science + Business Media

    Dr Nancy L Haigwood

  30. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges

    Article • Journal of Virology, March 2018, ASM Journals

    Dr Nancy L Haigwood

  31. Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials

    Article • Scientific Reports, January 2018, Springer Science + Business Media

    Dr Nancy L Haigwood

  32. Passive and active antibody studies in primates to inform HIV vaccines

    Article • Expert Review of Vaccines, January 2018, Taylor & Francis

    Dr Nancy L Haigwood

  33. Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses

    Article • SSRN Electronic Journal, January 2018, Elsevier

    Dr Nancy L Haigwood

  34. Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques

    Article • Nature Communications, December 2017, Springer Science + Business Media

    Dr Nancy L Haigwood

  35. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge

    Article • Journal of Virology, November 2017, ASM Journals

    Dr Nancy L Haigwood

  36. The Critical Role of Nonhuman Primates in Medical Research - White Paper

    Article • Pathogens and Immunity, August 2017, Case Western Reserve University

    Dr Nancy L Haigwood

  37. Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination

    Article • Vaccine, March 2017, Elsevier

    Dr Nancy L Haigwood

  38. Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques

    Article • PLOS One, February 2017, PLOS

    Dr Nancy L Haigwood

  39. Use of broadly neutralizing antibodies for HIV-1 prevention

    Article • Immunological Reviews, January 2017, Wiley

    Dr Nancy L Haigwood

  40. E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells

    Article • BMC Microbiology, July 2016, Springer Science + Business Media

    Dr Nancy L Haigwood

  41. Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates

    Article • Vaccine, June 2016, Elsevier

    Dr Nancy L Haigwood

  42. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides

    Article • Vaccine, May 2016, Elsevier

    Dr Nancy L Haigwood

  43. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques

    Article • Nature Medicine, March 2016, Springer Science + Business Media

    Dr Nancy L Haigwood

  44. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens

    Article • The Journal of Immunology, March 2016, The American Association of Immunologists

    Dr Nancy L Haigwood

  45. Animal models in HIV-1 protection and therapy

    Article • Current Opinion in HIV and AIDS, May 2015, Wolters Kluwer Health

    Dr Nancy L Haigwood

  46. Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies

    Article • Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, April 2015, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  47. Tied down by its own receptor

    Article • Nature, February 2015, Springer Science + Business Media

    Dr Nancy L Haigwood

  48. Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA

    Article • PLOS One, December 2014, PLOS

    Dr Nancy L Haigwood

  49. Development of Broadly Neutralizing Anti-HIV-1 Antibodies during Natural Infection through Early Epitope Acquisition and Subsequent Maturation

    Article • AIDS Research and Human Retroviruses, October 2014, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  50. Envelope Variants Circulating as Initial Neutralization Breadth Developed in Two HIV-Infected Subjects Stimulate Multiclade Neutralizing Antibodies in Rabbits

    Article • Journal of Virology, September 2014, ASM Journals

    Dr Nancy L Haigwood

  51. Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1

    Article • Journal of Virology, August 2014, ASM Journals

    Dr Nancy L Haigwood

  52. Vaccine Delivery to the Oral Cavity Using Coated Microneedles Induces Systemic and Mucosal Immunity

    Article • Pharmaceutical Research, March 2014, Springer Science + Business Media

    Dr Nancy L Haigwood

  53. Improvement of antibody responses by HIV envelope DNA and protein co-immunization

    Article • Vaccine, January 2014, Elsevier

    Dr Nancy L Haigwood

  54. HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans

    Article • PLOS One, September 2013, PLOS

    Dr Nancy L Haigwood

  55. SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans

    Article • Retrovirology, August 2013, Springer Science + Business Media

    Dr Nancy L Haigwood

  56. Neutralizing Polyclonal IgG Present during Acute Infection Prevents Rapid Disease Onset in Simian-Human Immunodeficiency Virus SHIVSF162P3-Infected Infant Rhesus Macaques

    Article • Journal of Virology, July 2013, ASM Journals

    Dr Nancy L Haigwood

  57. E2 multimeric scaffolds displaying HIV-1 Envelope regions elicit V3 and MPER-specific neutralizing antibody and T cell responses when combined with gp160 plasmid DNA

    Article • Frontiers in Immunology, January 2013, Frontiers

    Dr Nancy L Haigwood

  58. Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially

    Article • Vaccine, August 2012, Elsevier

    Dr Nancy L Haigwood

  59. Lessons in Nonhuman Primate Models for AIDS Vaccine Research: From Minefields to Milestones

    Article • Cold Spring Harbor Perspectives in Medicine, March 2012, Cold Spring Harbor Laboratory Press

    Dr Nancy L Haigwood

  60. Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8+ T Cells

    Article • PLOS One, February 2012, PLOS

    Dr Nancy L Haigwood

  61. Neutralizing Antibodies and Control of HIV: Moves and Countermoves

    Article • Current HIV/AIDS Reports, December 2011, Springer Science + Business Media

    Dr Nancy L Haigwood

  62. Sequential Immunization with a Subtype B HIV-1 Envelope Quasispecies Partially Mimics the In Vivo Development of Neutralizing Antibodies

    Article • Journal of Virology, March 2011, ASM Journals

    Dr Nancy L Haigwood

  63. HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells

    Article • Virology, November 2010, Elsevier

    Dr Nancy L Haigwood

  64. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques

    Article • Nature Medicine, October 2010, Springer Science + Business Media

    Dr Nancy L Haigwood

  65. Introduction

    Article • Vaccine, May 2010, Elsevier

    Dr Nancy L Haigwood

  66. Update on animal models for HIV research

    Article • European Journal of Immunology, August 2009, Wiley

    Dr Nancy L Haigwood

  67. Blocking and tackling HIV

    Article • Nature Medicine, August 2009, Springer Science + Business Media

    Dr Nancy L Haigwood

  68. Nonhuman primate models for pediatric AIDS

    Article • Neurotoxicology and Teratology, July 2009, Elsevier

    Dr Nancy L Haigwood

  69. The Infectious Molecular Clone and Pseudotyped Virus Models of Human Immunodeficiency Virus Type 1 Exhibit Significant Differences in Virion Composition with Only Moderate Differences in Infectivity and Inhibition Sensitivity

    Article • Journal of Virology, June 2009, ASM Journals

    Dr Nancy L Haigwood

  70. Immune Responses to Measles and Tetanus Vaccines Among Kenyan Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Children Pre- and Post-Highly Active Antiretroviral Therapy and Revaccination

    Article • The Pediatric Infectious Disease Journal, April 2009, Wolters Kluwer Health

    Dr Nancy L Haigwood

  71. High Specific Infectivity of Plasma Virus from the Pre-Ramp-Up and Ramp-Up Stages of Acute Simian Immunodeficiency Virus Infection

    Article • Journal of Virology, January 2009, ASM Journals

    Dr Nancy L Haigwood

  72. Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naïve Human Immunodeficiency Virus Controllers

    Article • Journal of Virology, November 2008, ASM Journals

    Dr Nancy L Haigwood

  73. Too close for comfort

    Article • Nature, August 2008, Nature

    Dr Nancy L Haigwood

  74. The Use of Nonhuman Primate Models in HIV Vaccine Development

    Article • PLoS Medicine, August 2008, PLOS

    Dr Nancy L Haigwood

  75. Pediatric AIDS: Maternal–Fetal and Maternal–Infant Transmission of Lentiviruses and Effects on Infant Development in Nonhuman Primates

    Article • January 2008, Elsevier

    Dr Nancy L Haigwood

  76. Transmission of HIV-1 in the Face of Neutralizing Antibodies

    Article • Current HIV Research, November 2007, Bentham Science Publishers

    Dr Nancy L Haigwood

  77. Mutations in Envelope gp120 Can Impact Proteolytic Processing of the gp160 Precursor and Thereby Affect Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Pseudoviruses

    Article • Journal of Virology, September 2007, ASM Journals

    Dr Nancy L Haigwood

  78. Article • Tuberculosis, August 2007, Elsevier

    Dr Nancy L Haigwood

  79. Macaques Infected with a CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV) Develop Broadly Reactive Anti-HIV Neutralizing Antibodies

    Article • Journal of Virology, March 2007, ASM Journals

    Dr Nancy L Haigwood

  80. Evidence for Persistent, Occult Infection in Neonatal Macaques following Perinatal Transmission of Simian-Human Immunodeficiency Virus SF162P3

    Article • Journal of Virology, November 2006, ASM Journals

    Dr Nancy L Haigwood

  81. Evaluation of Passively Transferred, Nonneutralizing Antibody-Dependent Cellular Cytotoxicity-Mediating IgG in Protection of Neonatal Rhesus Macaques against Oral SIVmac251 Challenge

    Article • The Journal of Immunology, September 2006, The American Association of Immunologists

    Dr Nancy L Haigwood

  82. Insights into neutralizing antibodies and HIV Envelope

    Article • Current Opinion in HIV and AIDS, July 2006, Wolters Kluwer Health

    Dr Nancy L Haigwood

  83. Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques

    Article • Journal of Virology, January 2006, ASM Journals

    Dr Nancy L Haigwood

  84. Differentiation of a passive vaccine and the humoral immune response toward infection: Analysis of phage displayed peptides

    Article • Vaccine, January 2006, Elsevier

    Dr Nancy L Haigwood

  85. Animal models for perinatal transmission of HIV-1

    Article • Frontiers in Bioscience, January 2006, Frontiers in Bioscience

    Dr Nancy L Haigwood

  86. High Maternal HIV-1 Viral Load During Pregnancy Is Associated With Reduced Placental Transfer of Measles IgG Antibody

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, December 2005, Wolters Kluwer Health

    Dr Nancy L Haigwood

  87. Infection with a molecularly cloned SIVsm virus elicits high titer homologous neutralizing antibodies with heterologous neutralizing activity

    Article • Journal of Medical Primatology, October 2005, Wiley

    Dr Nancy L Haigwood

  88. Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

    Article • Journal of Virology, September 2005, ASM Journals

    Dr Nancy L Haigwood

  89. Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines

    Article • Journal of Virology, August 2005, ASM Journals

    Dr Nancy L Haigwood

  90. Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge

    Article • Journal of Virology, December 2004, ASM Journals

    Dr Nancy L Haigwood

  91. New recombinant vaccines based on the use of prokaryotic antigen-display systems

    Article • Expert Review of Vaccines, December 2004, Taylor & Francis

    Dr Nancy L Haigwood

  92. Perinatal transmission of SHIV‐SF162P3 in Macaca nemestrina

    Article • Journal of Medical Primatology, September 2004, Wiley

    Dr Nancy L Haigwood

  93. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

    Article • Glycobiology, July 2004, Oxford University Press (OUP)

    Dr Nancy L Haigwood

  94. Passive Immunotherapy in Simian Immunodeficiency Virus-Infected Macaques Accelerates the Development of Neutralizing Antibodies

    Article • Journal of Virology, June 2004, ASM Journals

    Dr Nancy L Haigwood

  95. Protective Immunity to SIV Challenge Elicited by Vaccination of Macaques with Multigenic DNA Vaccines Producing Virus-Like Particles

    Article • AIDS Research and Human Retroviruses, April 2004, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  96. Immunoprophylaxis to Prevent Mother-to-Child Transmission of HIV-1

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, February 2004, Wolters Kluwer Health

    Dr Nancy L Haigwood

  97. Macaque blood-derived antigen-presenting cells elicit SIV-specific immune responses

    Article • Journal of Medical Primatology, November 2003, Wiley

    Dr Nancy L Haigwood

  98. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development

    Article • Proceedings of the National Academy of Sciences, November 2003, Proceedings of the National Academy of Sciences

    Dr Nancy L Haigwood

  99. Multigene DNA Priming-Boosting Vaccines Protect Macaques from Acute CD4+-T-Cell Depletion after Simian-Human Immunodeficiency Virus SHIV89.6P Mucosal Challenge

    Article • Journal of Virology, November 2003, ASM Journals

    Dr Nancy L Haigwood

  100. DNA vaccine strategies: candidates for immune modulation and immunization regimens

    Article • Methods, November 2003, Elsevier

    Dr Nancy L Haigwood

  101. Multigene DNA prime-boost vaccines for SHIV89.6P

    Article • Journal of Medical Primatology, August 2003, Wiley

    Dr Nancy L Haigwood

  102. Role of neutralizing antibodies in HIV infection

    Article • AIDS, January 2003, Wolters Kluwer Health

    Dr Nancy L Haigwood

  103. Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies

    Article • Journal of Virology, March 2002, ASM Journals

    Dr Nancy L Haigwood

  104. Progress and challenges in therapies for AIDS in nonhuman primate models

    Article • Journal of Medical Primatology, August 1999, Wiley

    Dr Nancy L Haigwood

  105. Immunization against SIVmne in macaques using multigenic DNA vaccines

    Article • Journal of Medical Primatology, August 1999, Wiley

    Dr Nancy L Haigwood

  106. Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm)

    Article • Journal of Medical Primatology, June 1999, Wiley

    Dr Nancy L Haigwood

  107. Protection from pathogenic SIV challenge using multigenic DNA vaccines

    Article • Immunology Letters, March 1999, Elsevier

    Dr Nancy L Haigwood

  108. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell–free virions from blood plasma

    Article • Nature Medicine, February 1999, Springer Science + Business Media

    Dr Nancy L Haigwood

  109. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys

    Article • Nature Medicine, February 1999, Springer Science + Business Media

    Dr Nancy L Haigwood

  110. Early Postinfection Antiviral Treatment Reduces Viral Load and Prevents CD4 + Cell Decline in HIV Type 2-Infected Macaques

    Article • AIDS Research and Human Retroviruses, November 1997, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  111. Titration of a Vaccine Stock Preparation of Human Immunodeficiency Virus Type 1 sf2 in Cultured Lymphocytes and in Chimpanzees

    Article • AIDS Research and Human Retroviruses, September 1996, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  112. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

    Article • Immunology Letters, June 1996, Elsevier

    Dr Nancy L Haigwood

  113. Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2

    Article • AIDS, December 1995, Wolters Kluwer Health

    Dr Nancy L Haigwood

  114. Characterization of a CD4-Expressing Macaque Cell Line That Can Detect Virus after a Single Replication Cycle and Can Be Infected by Diverse Simian Immunodeficiency Virus Isolates

    Article • Virology, November 1995, Elsevier

    Dr Nancy L Haigwood

  115. Fine Analysis of Humoral Antibody Response to Envelope Glycoprotein of SIV in Infected and Vaccinated Macaques

    Article • AIDS Research and Human Retroviruses, October 1994, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  116. Reduced Virus Load in Rhesus Macaques Immunized with Recombinant gp160 and Challenged with Simian Immunodeficiency Virus

    Article • AIDS Research and Human Retroviruses, February 1994, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  117. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.

    Article • Proceedings of the National Academy of Sciences, December 1993, Proceedings of the National Academy of Sciences

    Dr Nancy L Haigwood

  118. Nonaffinity Purification of Recombinant gp120 for Use in AIDS Vaccine Development

    Article • AIDS Research and Human Retroviruses, December 1993, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  119. B-Cell Abnormalities in AIDS: Stable and Clonally-Restricted Antibody Response in HIV-1 Infection

    Article • Scandinavian Journal of Immunology, October 1993, Wiley

    Dr Nancy L Haigwood

  120. HIV-1 Envelope gp120 Alters Astrocytes in Human Brain Cultures

    Article • AIDS Research and Human Retroviruses, May 1993, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  121. Molecular Profile of an Antibody Response to HIV-1 as Probed by Combinatorial Libraries

    Article • Journal of Molecular Biology, April 1993, Elsevier

    Dr Nancy L Haigwood

  122. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis

    Article • Journal of Experimental Medicine, October 1992, Rockefeller University Press

    Dr Nancy L Haigwood

  123. Inactivated Whole SIV Vaccine in Macaques: Evaluation of Protective Efficacy Against Challenge with Cell-Free Virus or Infected Cells

    Article • AIDS Research and Human Retroviruses, August 1992, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  124. SIV and FIV Vaccine Studies at UC Davis: 1991 Update

    Article • AIDS Research and Human Retroviruses, August 1992, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  125. Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120.

    Article • Journal of Clinical Investigation, June 1992, American Society for Clinical Investigation

    Dr Nancy L Haigwood

  126. Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine

    Article • Journal of General Virology, May 1992, Society for General Microbiology

    Dr Nancy L Haigwood

  127. Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.

    Article • Proceedings of the National Academy of Sciences, March 1992, Proceedings of the National Academy of Sciences

    Dr Nancy L Haigwood

  128. Functional and Immunological Characterization of SIV Envelope Glycoprotein Produced in Genetically Engineered Mammalian Cells

    Article • AIDS Research and Human Retroviruses, November 1991, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  129. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

    Article • Proceedings of the National Academy of Sciences, July 1991, Proceedings of the National Academy of Sciences

    Dr Nancy L Haigwood

  130. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells

    Article • Nucleic Acids Research, January 1991, Oxford University Press (OUP)

    Dr Nancy L Haigwood

  131. Antibody Reactivity to Deletion Mutants of the HIV-1 SF2 Envelope

    Article • Intervirology, January 1991, Karger Publishers

    Dr Nancy L Haigwood

  132. Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein.

    Article • Proceedings of the National Academy of Sciences, August 1990, Proceedings of the National Academy of Sciences

    Dr Nancy L Haigwood

  133. Importance of Hypervariable Regions of HIV-1 gp120 in the Generation of Virus Neutralizing Antibodies

    Article • AIDS Research and Human Retroviruses, July 1990, Mary Ann Liebert Inc

    Dr Nancy L Haigwood

  134. Variants of human tissue-type plasminogen activator substituted at the protease cleavage site and glycosylation sites, and truncated at the N- and C-termini

    Article • Protein Engineering Design and Selection, January 1989, Oxford University Press (OUP)

    Dr Nancy L Haigwood

  135. Locations of three repetitive sequence families found in BALB/c adult β-globin clones

    Article • Nucleic Acids Research, January 1981, Oxford University Press (OUP)

    Dr Nancy L Haigwood

  136. DNA sequence organization of the β-globin complex in the BALB/c mouse

    Article • Cell, August 1980, Elsevier

    Dr Nancy L Haigwood

  137. The recognition site of type II restriction enzyme BglI is interrupted

    Article • Gene, May 1980, Elsevier

    Dr Nancy L Haigwood

  138. Gene Enrichment

    Article • January 1979, Springer Science + Business Media

    Dr Nancy L Haigwood

  139. Nonhuman Primate Models for AIDS

    Article • Springer Science + Business Media

    Dr Nancy L Haigwood